Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 12-Month High on Analyst Upgrade

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) reached a new 52-week high on Thursday after BTIG Research raised their price target on the stock from $24.00 to $25.00. BTIG Research currently has a buy rating on the stock. Adaptive Biotechnologies traded as high as $23.52 and last traded at $23.5530, with a volume of 512775 shares changing hands. The stock had previously closed at $22.56.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley raised their price target on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.83.

Insider Buying and Selling

In other news, insider Harlan S. Robins sold 492,400 shares of the business’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. The trade was a 37.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. The trade was a 41.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,305,787 shares of company stock valued at $27,828,563. Corporate insiders own 5.70% of the company’s stock.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG raises target and reiterates Buy: BTIG Research increased its price target from $24 to $25 and maintained a “Buy” rating, implying further upside from recent trading levels. Benzinga analyst price target report
• Positive Sentiment: Second-quarter revenue exceeded expectations: Adaptive Biotechnologies reported $71.55 million in revenue, above the $65.44 million consensus estimate, with year-over-year growth of 21.5%. The company also reported an adjusted loss of $0.10 per share versus the $0.13 expected loss, improving from a $0.17 loss a year earlier. Zacks second-quarter earnings report
• Positive Sentiment: Brokerage sentiment remains constructive: The company has a consensus “Moderate Buy” rating, with five Buy ratings, one Hold and one Sell. Institutional investors own approximately 99% of outstanding shares, indicating substantial professional-investor participation.
• Neutral Sentiment: Earnings-call details are being reviewed: The Q2 2026 conference call transcript may provide additional information on commercial momentum, partnerships and the outlook for Adaptive’s immune-repertoire sequencing business. Q2 2026 earnings call transcript
• Negative Sentiment: Profitability remains a concern: Despite the adjusted earnings beat, Adaptive Biotechnologies remains unprofitable, with a reported negative net margin and negative return on equity. One earnings summary cited a $0.25 per-share GAAP loss, highlighting the difference between adjusted and GAAP results. Adaptive Biotechnologies second-quarter financial results
• Negative Sentiment: Insider selling adds a cautionary signal: Director Harlan Robins sold 492,400 shares worth approximately $10.8 million, reducing his position by 37.75%. The sale was made under a pre-arranged Rule 10b5-1 plan, which lessens—but does not eliminate—the signaling concern. Adaptive Biotechnologies insider sale report

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of ADPT. California State Teachers Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after buying an additional 941 shares during the last quarter. Captrust Financial Advisors raised its stake in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares in the last quarter. Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 46.4% during the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after buying an additional 1,401 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after buying an additional 1,532 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Trading Up 4.2%

The stock has a fifty day simple moving average of $19.05 and a 200-day simple moving average of $16.56. The company has a market capitalization of $3.76 billion, a PE ratio of -71.06 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the business posted ($0.20) EPS. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.